Antihypertensive Drugs Market Outlook 2031
- The global antihypertensive drugs market was valued at US$ 30.2 Bn in 2021
- The global market is projected to grow at a CAGR of 3.0% from 2022 to 2031
- The global antihypertensive drugs market is anticipated to reach more than US$ 40 Bn by the end of 2031
Overview of Antihypertensive Drugs Market
Antihypertensive medications are used to treat high blood pressure. Different types of antihypertensive drugs are available in the market. These help lower blood pressure. Some remove excess fluid and salt from the body, while others help relax and widen blood vessels or slow the heart rate. A person could respond better and experience fewer side effects to one drug than to another. Some patients require more than one antihypertensive agent to lower blood pressure.
Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7718
Hypertension is a preventable risk factor for atherosclerotic disease and ischemic heart disease. A number of patients maintain suboptimal blood pressure control despite the availability of modern and effective antihypertensive drugs. Most hypertensive patients require a combination of antihypertensive agents to achieve treatment goals. Under combination therapy, another class of blood pressure medication is added to the first drug to increase its effectiveness. The antihypertensive drugs market has reasonably high unmet demand, which indicates the lack of effective products. This presents significant opportunities for new entrants to capitalize on the unmet needs, largely due to poor patient compliance with products currently available in the market.
Trends in antihypertensive medication in stroke survivors could provide important insights into gaps in secondary prevention that can guide improved interventions in the future. Healthcare companies are increasing R&D in the field of genomics and resistant hypertension treatment to gain a competitive edge over other market players.
Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=7718
Launch of New Disease-modifying Therapies to Drive Global Antihypertensive Drugs Market
Innovative antihypertensive drugs and drug therapies are expected to offer favorable outcomes, as these effectively target disease progression. The current scenario in the global antihypertensive drugs market is expected to change due to the launch of new therapies for diseases such as angiotensin II receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, and calcium channel blockers (CCB) during the forecast period.
Currently, physicians prescribe fewer diuretics and beta-blockers, common first-line agents for hypertension, and more ACE and CHF inhibitors. ACE inhibitors reduce mortality and morbidity in cardiovascular patients; however, this is not true for CCBs. If control is not available on beta-blockers, diuretics, or ACE inhibitors, short-acting CHFs should be avoided and alternatives should be considered. Unlike ACE inhibitors, ARBs do not cause cough. Therefore, launch of innovative drug/therapeutic molecules with disease-modifying properties and improved efficacy and safety is expected to drive the global antihypertensive drugs market in the next few years.
Promising Products in Pipeline to Boost Demand for Antihypertensive Drugs
Treatments for hypertension are relatively potent. Several drugs are being studied in clinical trials, including those with disease-modifying properties, better safety, and effectiveness, which can reduce disease progression significantly.
Launch of new products with improved efficiency and safety is expected to drive the market. Bayer’s candesartan cilexetil/nifedipine (phase III), Boryung Pharmaceuticals’ fimasartan/amlodipine (phase III), and Takeda Pharmaceuticals’ diuretic azilsartan/amlodipine/hydrochlorothiazide (phase III) are some of the drugs under development.
Enquiry before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=7718
Companies Establish Stable Revenue Streams by Augmenting Production of Angiotensin Receptor Blockers
In terms of therapy type, the global antihypertensive drugs market has been classified into diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, vasodilators, calcium channel blockers, renin inhibitors, alpha-blockers, and others. The angiotensin receptor blockers segment is projected to dominate the global market during the forecast period. The segment is expected to grow at a high CAGR from 2021 to 2031. Angiotensin II receptor blockers (ARBs) have a similar effect to ACE inhibitors, another type of blood pressure drug, but work on a different mechanism.
High Salt Intake to Propel Demand for Antihypertensive Drugs for Primary Hypertension Management
Based on type, the global antihypertensive drugs market has been bifurcated into primary hypertension and secondary hypertension. The primary hypertension segment is projected to dominate the global market during the forecast period. The segment is anticipated to grow at a high CAGR from 2021 to 2031. Hypertension has become a global health concern over the last decade. In the developed world, salt intake is generally above the recommended quantity among children. Similar trend exists in the developing world. Positive sodium balance is needed for growth in the first year of life; however, high salt intake could have harmful cardiovascular consequences.
Request Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=7718
Increase in Geriatric Population with Comorbidities Driving Need for Combination Therapy
In terms of medication, the global antihypertensive drugs market has been segregated into monotherapy, combination therapy, and fixed dose combinations. The combination therapy segment is projected to dominate the market, with significant revenue share by 2031. The segment is anticipated to advance at a high CAGR from 2021 to 2031. Rise in geriatric population with comorbid conditions such as congenital heart disease; and focus on combination therapies are driving the combination therapy segment. Thus, manufacturers are increasing the production of combination antihypertensive drugs to meet the needs of elderly patients with comorbidities.
Broad Medicine Portfolio to Boost Hospital Pharmacies Segment
Based on distribution channel, the global antihypertensive drugs market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment dominated the global market in 2021. Hospital pharmacies usually stock a wide range of medicines, including specialized and investigational medications. Hospital pharmacies are increasing the availability of hypertension management devices to broaden their income sources.
Ask References @ https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=7718
Analysis of Key Players in Antihypertensive Drugs Market
The global antihypertensive drugs market is consolidated, with a small number of leading players accounting for major share. Large numbers of companies are investing in research & development activities. Diversification of product portfolios and mergers & acquisitions are important strategies adopted by key players. Pfizer, Inc., Sanofi S.A, Novartis AG, Boehringer Ingelheim GmbH, Actelion Ltd., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited are the prominent players operating in the global market.
Key Developments in Global Antihypertensive Drugs Market
- In April 2021, Radnor Biopharma developed a hormone-targeting treatment for hypertension
- In 2018, CFDA provided a new clinical approval process for a company to proceed with a clinical trial if the Center for Drug Evaluation Act has no comments on the application within a given period of time
- In July 2018, Daiichi Sankyo Company Limited’s antihypertensive drug Sieweika (olmesartan amlodipine tablet) was officially approved in China
Each of these players has been profiled in the antihypertensive drugs market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
About Us
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update – https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact Us:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: [email protected]